Epidemiologic, Virologic, and Host Genetic Factors of Norovirus Outbreaks in Long-term Care Facilities

Clinical Infectious Diseases

Volumn 62, Issue 1, 2016, Pages 1-10

  Costantini, Veronica P ^a   Cooper, Emilie M ^a   Hardaker, Hope L ^b   Lee, Lore E ^b   Bierhoff, Marieke ^a,c   Biggs, Christianne ^b   Cieslak, Paul R ^b   Hall, Aron J ^a   Vinjé, Jan ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OREGON HEALTH AUTHORITY   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

long term care facilities; norovirus; secretor status; shedding

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; HOST FACTOR; BLOOD GROUP ANTIGEN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIARRHEA; EPIDEMIC; FATIGUE; FEMALE; GENOTYPE; GIARDIA; HEREDITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; NOROVIRUS INFECTION; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE HOMOLOGY; VERY ELDERLY; VIRUS DETECTION; VIRUS LOAD; VIRUS SHEDDING; VOMITING; CALICIVIRIDAE INFECTIONS; CLASSIFICATION; FECES; GASTROENTERITIS; GENETICS; LONG TERM CARE; MIDDLE AGED; NOROVIRUS; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GROUP ANTIGENS; CALICIVIRIDAE INFECTIONS; DISEASE OUTBREAKS; FECES; FEMALE; GASTROENTERITIS; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NOROVIRUS; PROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84954312843     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ747     Document Type: Article

References (40)

1. Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: A systematic review and meta-analysis. Lancet Infect Dis 2014; 14:725-30.
2. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-205.
3. Hall AJ, Wikswo ME, Manikonda K, Roberts VA, Yoder JS, Gould LH. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis 2013; 19:1305-9.
4. Rosenthal NA, Lee LE, Vermeulen BA, et al. Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003-2006. Epidemiol Infect 2011; 139:286-94.
5. Trivedi TK, DeSalvo T, Lee L, et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. JAMA 2012; 308:1668-75.
6. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015; 53:373-81.
7. Green K. Caliciviridae: The norovirus. In: Knipe DH, Howley PM, Cohen JI, et al. Field's virology. 6th ed. Vol 2. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:583-609.
8. Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J Clin Microbiol 2010; 48:168-77.
9. Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis 2011; 17:1389-95.
10. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histoblood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002; 122:1967-77.
11. Bucardo F, Kindberg E, Paniagua M, et al. Genetic susceptibility to symptomatic norovirus infection in Nicaragua. J Med Virol 2009; 81:728-35.
12. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 norovirus infection. PLoS One 2009; 4:e5593.
13. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53.
14. Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis 2010; 16:81-7.
15. Thorven M, Grahn A, Hedlund KO, et al. A homozygous nonsense mutation (428G->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol 2005; 79:15351-5.
16. Currier RL, Payne DC, Staat MA, et al. Innate susceptibility to norovirus infections influenced by FUT2 genotype in a United States pediatric population. Clin Infect Dis 2015; 60:1631-8.
17. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386-93.
18. Kirby AE, Shi J, Montes J, Lichtenstein M, Moe CL. Disease course and viral shedding in experimental Norwalk virus and Snow Mountain virus infection. J Med Virol 2014; 86:2055-64.
19. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008; 14:1553-7.
20. Hall AJ, Vinje J, Lopman B, et al. Update norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011; 60(RR-3):1-18.
21. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28:2731-9.
22. KindbergE,HejdemanB,BrattG, et al.Anonsensemutation(428G->A) in the fucosyltransferase FUT2 gene affects the progressionofHIV-1 infection. AIDS 2006; 20:685-9.
23. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002; 76: 12335-43.
24. Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 1992; 8:275-82.
25. Administration on Aging. A profile of older Americans, 2012. Available at: http:// www.aoa.acl.gov/Aging-Statistics/Profile/2012/docs/2012profile.pdf. Accessed 9 March 2015.
26. Centers for Disease Control and Prevention. Emergence of new norovirus strain GII.4 Sydney-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:55.
27. Chan MC, Sung JJ, Lam RK, et al. Fecal viral load and norovirus-associated gastroenteritis. Emerg Infect Dis 2006; 12:1278-80.
28. Sukhrie FH, Teunis P, Vennema H, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 2012; 54:931-7.
29. Teunis PF, Sukhrie FH, Vennema H, Bogerman J, Beersma MF, Koopmans MP. Shedding of norovirus in symptomatic and asymptomatic infections. Epidemiol Infect 2015; 143:1710-7.
30. Tu ET, Bull RA, Kim MJ, et al. Norovirus excretion in an aged-care setting. J Clin Microbiol 2008; 46:2119-21.
31. Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K, Matsuzaki Y. Duration of norovirus excretion and the longitudinal course of viral load in norovirus-infected elderly patients. J Hosp Infect 2010; 75:42-6.
32. PartridgeDG, EvansCM, Raza M,KudesiaG, ParsonsHK. Lessons froma large norovirus outbreak: impact of viral load, patient age and ward design on duration of symptoms and shedding and likelihood of transmission. J Hosp Infect 2012; 81:25-30.
33. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis 2014; 209:1016-22.
34. Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008; 80:1468-76.
35. de Rougemont A, Ruvoen-Clouet N, Simon B, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol 2011; 85:4057-70.
36. Yen C, Wikswo ME, Lopman BA, Vinje J, Parashar UD, Hall AJ. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin Infect Dis 2011; 53:568-71.
37. Leshem E, Wikswo M, Barclay L, et al. Effects and clinical significance of GII.4 Sydney norovirus, United States, 2012-2013. Emerg Infect Dis 2013; 19:1231-8.
38. Miura T, Sano D, Suenaga A, et al. Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J Virol 2013; 87:9441-51.
39. Ruvoen-Clouet N, Magalhaes A, Marcos-Silva L, et al. Increase in genogroup II.4 norovirus host spectrum by CagA-positive Helicobacter pylori infection. J Infect Dis 2014; 210:183-91.
40. Ramani S, Neill FH, Opekun AR, et al. Mucosal and cellular immune responses to Norwalk virus. J Infect Dis 2015; 212:397-405.